{"altmetric_id":12969153,"citation":{"altmetric_jid":"clinicaltrialsgov","authors":["CTD Holdings, Inc."],"first_seen_on":"2016-10-24T22:37:50+00:00","issns":[],"journal":"ClinicalTrials.gov","last_mentioned_on":1506902400,"links":["https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02939547?term=%22Niemann+Pick+disease+type+C%22&recr=Open&lup_s=10\/21\/2015&lup_d=365&show_rss=Y&sel_rss=mod14&utm_source=twitterfeed&utm_medium=twitter","https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02939547"],"nct_id":"NCT02939547","pubdate":"2016-09-21T00:00:00+00:00","publisher":"ClinicalTrials.gov","title":"Study of the Pharmacokinetics of Trappsol and Effects on Potential Biomarkers of Niemann-Pick C1 (NPC1)","type":"clinical_trial_study_record"},"altmetric_score":{"score":66.5,"score_history":{"1y":66.5,"6m":64,"3m":64,"1m":36,"1w":36,"6d":36,"5d":36,"4d":4,"3d":4,"2d":4,"1d":0,"at":66.5},"context_for_score":{"all":{"total_number_of_other_articles":8462593,"mean":7.1086032149407,"rank":142110,"this_scored_higher_than_pct":98,"this_scored_higher_than":8320426,"rank_type":"exact","sample_size":8462593,"percentile":98},"similar_age_3m":{"total_number_of_other_articles":248490,"mean":12.906188901722,"rank":9356,"this_scored_higher_than_pct":96,"this_scored_higher_than":239132,"rank_type":"exact","sample_size":248490,"percentile":96},"this_journal":{"total_number_of_other_articles":24884,"mean":10.564041634851,"rank":547,"this_scored_higher_than_pct":97,"this_scored_higher_than":24335,"rank_type":"exact","sample_size":24884,"percentile":97},"similar_age_this_journal_3m":{"total_number_of_other_articles":944,"mean":9.9656394485684,"rank":23,"this_scored_higher_than_pct":97,"this_scored_higher_than":921,"rank_type":"exact","sample_size":944,"percentile":97}}},"demographics":{"poster_types":{"member_of_the_public":1},"users":{"twitter":{"cohorts":{"Members of the public":1}}}},"counts":{"total":{"posts_count":17},"news":{"unique_users_count":9,"unique_users":["nasdaq","digital_journal","bioportfolio","benzinga","wall_street_online_denmark","stockhouse","biomed_reports","pettinga_stock_market","biospace"],"posts_count":16},"twitter":{"unique_users_count":1,"unique_users":["RDTrials"],"posts_count":1}},"posts":{"twitter":[{"url":"http:\/\/twitter.com\/RDTrials\/statuses\/789122575146201089","license":"gnip","citation_ids":[12969153],"posted_on":"2016-10-20T15:14:17+00:00","author":{"name":"Clinical Trials RD","image":"https:\/\/abs.twimg.com\/sticky\/default_profile_images\/default_profile_5_normal.png","id_on_source":"RDTrials","tweeter_id":"971840539","geo":{"lt":null,"ln":null},"followers":7},"tweet_id":"789122575146201089"}],"news":[{"title":"CTD Holdings Enrolls First Patient in European Phase I\/II Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=30970013556&p=1pl&v=1&x=11urQw_Pg1v9FEAYKHfArA","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-06-21T12:00:00+00:00","summary":"ALACHUA, FL -- (Marketwired) -- 06\/21\/17 -- CTD Holdings, Inc.(OTCQB:CTDH) The Phase I\/II clinical trial, which will include additional sites in the UK and Sweden and is also expected to be expanded to Italy, will require 12 patients to be fully\u2026","author":{"name":"NASDAQ","url":"http:\/\/www.nasdaq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/839\/normal\/Screen_Shot_2016-01-27_at_11.14.52.png?1453893369"}},{"title":"CTD Holdings Enrolls First Patient in European Phase I\/II Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C - Press Release","url":"http:\/\/ct.moreover.com\/?a=30970160181&p=1pl&v=1&x=qINDR1i5InawvW95O9YBEA","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-06-21T12:22:31+00:00","summary":"ALACHUA, FL--(Marketwired - June 21, 2017) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it has enrolled the first patient in\u2026","author":{"name":"Digital Journal","url":"http:\/\/www.digitaljournal.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/223\/normal\/image.png?1371424893"}},{"title":"CTD Holdings Enrolls First Patient in European Phase I\/II Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=30970161967&p=1pl&v=1&x=wvhmBGa3b6aAojw8FU6RBw","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-06-21T00:00:00+00:00","summary":"ALACHUA, FL--(Marketwired - June 21, 2017) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it has enrolled the first patient in\u2026","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"CTD Holdings Enrolls First Patient in European Phase I\/II Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=30970468131&p=1pl&v=1&x=Cdw6HbFR3Wvltef3qJsUFw","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-06-21T12:00:00+00:00","summary":"Company Expects Final Data from Trial by End of 2018 ALACHUA, FL --( - June 21, 2017) - CTD Holdings, Inc.","author":{"name":"Benzinga","url":"http:\/\/www.benzinga.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/738\/normal\/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}},{"title":"CTD Holdings Announces First Patient Dosed in Phase I\/II Clinical Trial to Evaluate Trappsol(R) Cyclo(TM) in Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=31255309523&p=1pl&v=1&x=JOlqsk3l9MnIXJVRcCO3mA","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-07-19T12:00:00+00:00","summary":"ALACHUA, FL -- (Marketwired) -- 07\/19\/17 -- CTD Holdings, Inc.(OTCQB:CTDH) The first patient was dosed by Dr.","author":{"name":"NASDAQ","url":"http:\/\/www.nasdaq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/839\/normal\/Screen_Shot_2016-01-27_at_11.14.52.png?1453893369"}},{"title":"CTD Holdings Announces First Patient Dosed in Phase I\/II Clinical Trial to Evaluate Trappsol(R) Cyclo(TM) in Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=31255380146&p=1pl&v=1&x=cJ4PGrT2sOV6HkWh7VXsmQ","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-07-19T12:11:30+00:00","summary":") - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of disease, today announced that the first patient has been dosed intravenously in the Company's European Phase I\/II\u2026","author":{"name":"Wall Street Online Denmark","url":"http:\/\/www.wallstreet-online.de","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/836\/normal\/Screen_Shot_2016-01-27_at_11.09.05.png?1453892964"}},{"title":"CTD Holdings Announces First Patient Dosed in Phase I\/II Clinical Trial to Evaluate Trappsol(R) Cyclo(TM) in Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=31255409924&p=1pl&v=1&x=WnpvZ6_7CKAWXmfByXsH1w","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-07-19T12:14:31+00:00","summary":"Study Evaluating Safety and Efficacy of Trappsol(R) Cyclo(TM) in a Multi-center European Trial Company Expects Final Data from Trial by End of 2018 ALACHUA, FL --(Marketwired - July 19, 2017) - CTD Holdings, Inc.","author":{"name":"Stockhouse","url":"http:\/\/www.stockhouse.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/768\/normal\/Screen_Shot_2016-01-26_at_16.49.41.png?1453827072"}},{"title":"CTD Holdings Announces First Patient Dosed in Phase I\/II Clinical Trial to Evaluate Trappsol(R) Cyclo(TM) in Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=31255429469&p=1pl&v=1&x=3iFta5BIKzcB83cdtxp9lA","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-07-19T12:15:58+00:00","summary":"Study Evaluating Safety and Efficacy of Trappsol(R) Cyclo(TM) in a Multi-center European Trial Company Expects Final Data from Trial by End of 2018 ALACHUA, FL --(Marketwired - July 19, 2017) - CTD Holdings, Inc.","author":{"name":"Benzinga","url":"http:\/\/www.benzinga.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/738\/normal\/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}},{"title":"CTD Holdings Announces First Patient Dosed in Phase I\/II Clinical Trial to Evaluate Trappsol(R) Cyclo(TM) in Niemann-Pick Disease Type C - Press Release","url":"http:\/\/ct.moreover.com\/?a=31255551339&p=1pl&v=1&x=qsnqitUN8o70x62hIMyXtQ","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-07-19T12:29:02+00:00","summary":"ALACHUA, FL--(Marketwired - July 19, 2017) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of disease, today announced that the first patient has been dosed\u2026","author":{"name":"Digital Journal","url":"http:\/\/www.digitaljournal.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/223\/normal\/image.png?1371424893"}},{"title":"CTD Holdings Announces First Patient Dosed in Phase I\/II Clinical Trial to Evaluate Trappsol(R) Cyclo(TM) in Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=31255553473&p=1pl&v=1&x=KGMKtyp5qwan9unUOP8cCA","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-07-19T00:00:00+00:00","summary":"ALACHUA, FL--(Marketwired - July 19, 2017) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of disease, today announced that the first patient has been dosed\u2026","author":{"name":"Bioportfolio","url":"http:\/\/www.bioportfolio.com\/","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/821\/normal\/Screen_Shot_2015-12-11_at_16.36.54.png?1449851849"}},{"title":"CTD Holdings Announces First Patient Dosed in Phase I\/II Clinical Trial to Evaluate Trappsol(R) Cyclo(TM) in Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=31299364535&p=1pl&v=1&x=3BnAAUELsLcZAYBVl-Uh_A","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-07-24T02:21:52+00:00","summary":"Study Evaluating Safety and Efficacy of Trappsol\u00ae Cyclo\u2122 in a Multi-center European Trial ALACHUA, FL --(Marketwired - July 19, 2017) - CTD Holdings, Inc.","author":{"name":"BioMed Reports","url":"http:\/\/www.biomedreports.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/913\/normal\/Screen_Shot_2016-02-02_at_15.18.15.png?1454426307"}},{"title":"CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=31983188475&p=1pl&v=1&x=LlH4om36Wx0wPHJCo3yjPg","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-09-28T12:00:00+00:00","summary":"Company Expects Final Data from Trial in 2018 ALACHUA, FL -- (Marketwired) -- 09\/28\/17 -- CTD Holdings, Inc.","author":{"name":"NASDAQ","url":"http:\/\/www.nasdaq.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/839\/normal\/Screen_Shot_2016-01-27_at_11.14.52.png?1453893369"}},{"title":"CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=31983271012&p=1pl&v=1&x=5y2ueE2NPzVYgMwEstokYw","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-09-28T12:00:00+00:00","summary":") -. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it has enrolled the first patient in the Company's US Phase I clinical\u2026","author":{"name":"Pettinga: Stock Market","url":"http:\/\/markets.pettinga.com\/pettinga","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/670\/normal\/Screen_Shot_2016-01-26_at_13.58.04.png?1453816748"}},{"title":"CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C - Press Release","url":"http:\/\/ct.moreover.com\/?a=31983325494&p=1pl&v=1&x=PoI7dcQbLvuEiQ9Vh6uRcw","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-09-28T12:17:49+00:00","summary":"ALACHUA, FL--(Marketwired - September 28, 2017) - CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical need, today announced that it has\u2026","author":{"name":"Digital Journal","url":"http:\/\/www.digitaljournal.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/000\/223\/normal\/image.png?1371424893"}},{"title":"CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=31985185996&p=1pl&v=1&x=ztrWTpa0zZMEIngN0xXAzQ","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-09-28T12:00:00+00:00","summary":"CTD Holdings Enrolls First Patient in US Phase I Clinical Trial of Trappsol(R) Cyclo(TM) for Treatment of Niemann-Pick Disease Type C Company Expects Final Data from Trial in 2018 ALACHUA, FL--(Marketwired - September 28, 2017) - CTD Holdings, Inc.","author":{"name":"Benzinga","url":"http:\/\/www.benzinga.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/738\/normal\/Screen_Shot_2016-01-26_at_15.59.27.png?1453824001"}},{"title":"CTD Holdings Enrolls First Patient In U.S. Phase I Clinical Trial Of Trappsol Cyclo For Treatment Of Niemann-Pick Disease Type C","url":"http:\/\/ct.moreover.com\/?a=32024150256&p=1pl&v=1&x=e6mmNmIRafGqynh5BNg5EA","license":"public","citation_ids":[12969153,12165130],"posted_on":"2017-10-02T00:00:00+00:00","summary":"Company Expects Final Data from Trial in 2018 ALACHUA, FL--(Marketwired - September 28, 2017) - CTD Holdings, Inc.","author":{"name":"Biospace","url":"http:\/\/www.biospace.com","image":"https:\/\/s3.amazonaws.com\/weyland.altmetric.com\/news_sources\/logos\/000\/001\/375\/normal\/biospace.png?1437140433"}}]}}